Skip to content

A Study Exploring Health Issues and Recovery Challenges in Participants Undergoing Gallbladder Surgery

IMPACT CHOLE: Assessment of Morbidity and Burden of Illness through a Tracking Initiative in a Prospective, Observational Study of Cholecystitis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/107678
Enrollment
218
Registered
2026-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K810- Acute cholecystitis

Interventions

Intervention1: Nil: Nil

Sponsors

Intuitive Surgical India Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult patients (18 years or more) undergoing cholecystectomy for cholecystitis/gallstone disease. 2. The subject is scheduled to undergo cholecystectomy for acute cholecystitis classified as grade I or II, as assessed by the physician in accordance with the Tokyo guidelines.

Exclusion criteria

Exclusion criteria: 1. The subject has a contraindication to general anesthesia or surgical procedures. 2. The subject has been taking daily pain medications for more than 6 weeks. 3. The subject is scheduled to undergo a concomitant procedure. 4. The subject has a known bleeding or coagulation disorder. 5. The subject is pregnant or suspected to be pregnant. 6. The subject has a psychological or psychiatric disorder, or a severe systemic illness that may hinder compliance with study requirements or the ability to provide informed consent. 7. The subject is currently enrolled in another interventional or investigational research study.

Design outcomes

Primary

MeasureTime frame
To compare the change in Health-Related Quality of Life (HRQoL), as measured by the EQ-5D-3L index score, from pre-operative baseline to postoperative day 30 between patients undergoing laparoscopic or robotic-assisted cholecystectomy.Timepoint: At baseline, and at Day 3 (+1) day, day 7 (+1) day, Day 14 (+3) days, and Day 30 (+5) days post surgery

Secondary

MeasureTime frame
To compare perioperative outcomes: operative time, estimated blood loss, conversion to open surgery, intraoperative complications, postoperative complications, post-anesthesia care unit (PACU) time, Intensive Care Unit (ICU) stay, & length of hospital stay (LOS).Timepoint: At discharge;To compare patient-reported pain intensity as assessed by the Numeric Rating Scale (NRS) at predefined time pointsTimepoint: At baseline, & at 6, 12, 24 hours, day 3, & day 7 post surgery;To compare cumulative analgesic consumption during the first 7 postoperative days.Timepoint: At Day 7 post surgery;To compare time to return to activities of daily living & return to work.Timepoint: At day 3, 7 & 14 post surgery.;To collect optional cost data to evaluate direct treatment costs, costs of adverse event (AE) management, readmissions & reoperations & perform exploratory cost-effectiveness analyses (e.g., cost per QALY gained using EQ-5D utility values).Timepoint: At baseline & at 30 days post surgery.;To document survival status, EQ-5D-3L, bile duct injury, port side hernia, and any costs related to readmission and reoperation.Timepoint: 3, 6, and 12 months post surgery

Countries

India

Contacts

Public ContactDr Akhil Dahiya

Intuitive Surgical India Pvt. Ltd.

akhil.dahiya@intusurg.com08045505100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026